Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Temperature InduCed K+ channel as a tool to treat neuropathic pain

Descrizione del progetto

Uno strumento innovativo per il trattamento del dolore neuropatico

Il nostro corpo ha sviluppato un’abilità straordinaria di rilevare e rispondere a stimoli nocivi, essenziale per il nostro benessere e la sopravvivenza. In caso di lesioni persistenti, le componenti sia del sistema nervoso periferico che di quello centrale legate alle vie di trasmissione del dolore si modificano, causando una patologia nota come dolore cronico. Il progetto TICK, finanziato dall’UE, si concentra sul dolore neuropatico, una condizione di ipersensibilità a causa della quale il cervello traduce stimoli non dolorosi in sensazioni dolorose. Il progetto propone un approccio innovativo per inibire l’attivazione delle cellule neuronali associate al dolore: una soluzione promettente al problema dell’efficacia limitata dei farmaci per il sistema nervoso centrale contro il dolore cronico e neuropatico.

Obiettivo

Non-invasive Control of Neuronal Activity can in principle contribute to the medical treatment of pathologic states in which the electrical activity of neurons is impaired, as in seizures and in chronic pain (CP). To this end, we are developing and validating proteins regulated by non-toxic external stimuli that freely penetrate tissues. TICK (Temperature InduCed K+ channel) is a K+ Channel reversibly regulated by Temperature in a very narrow range (37-40 °C). The open channel drives a large K+ efflux that hyperpolarizes the neuronal cell and prevents action potential firing. The effect is reversible and the channel closes when the temperature drops below 40°C. The perfect match with the temperature requirement for humans, prompts us to consider TICK as a promising medical tool for neuronal inhibition, in the treatment of CP. Chronic pain (CP) is a medical condition affecting around 20% of adults in Europe, characterised by an abnormal duration of pain (> 12 weeks). CP is extremely hard to treat, with only about half of patients reporting adequate pain relief. This situation is even worse for neuropathic pain (NP), a specific class of CP affecting 8% of global population, which leads the brain to interpret as pain normally non-painful stimuli. NP is difficult to treat and to diagnose, due to the large number of entities involved (cells, genes and proteins working in synergy). Drugs targeting the central nervous system (e.g. antidepressants and opioids) provide only partial pain relief and are nonspecific, also causing side effects like addiction and nausea, thus restraining their adoption for prolonged treatments. TICK has no side effects and also overcomes the unavoidable limit of similar optogenetic treatment previously proposed: the need of fiber optic implant to bring light. The first version of these channels, has already been tested preliminary on rats. During this project we plan to further validate the treatment and explore its commercial potential.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2020-PoC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

UNIVERSITA DEGLI STUDI DI MILANO
Contributo netto dell'UE
€ 150 000,00
Indirizzo
Via Festa Del Perdono 7
20122 Milano
Italia
Regione
Nord-Ovest Lombardia Milano
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)